Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moderna COVID-19 vaccination in adults with primary immune deficiencies
NL-OMON52126Completed
- Sponsor
- Erasmus MC
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of elasomeran in coronavirus disease 2019 (COVID-19) (7 arms), sponsored by Erasmus MC. Primary endpoint: Antibody response in isolated antibody deficiency cohort. Started Mar 2021; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON52126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52126.